Organoids are derived from biopsies and tissues sampled from patients or subjects (usually termed Patient-Derived Organoids, or PDOs). PDOs are self-organising cell structures that mimic the tissue or organ from which they are derived – they are often termed ‘mini-organs’.

PDOs provide a step-change improvement in the ability to screen drugs in models that are predictive of patient responses to those drugs, providing better data today and better drugs tomorrow.

Derived in the lab from normal subjects or patient biopsy tissue from a wide variety of disease states

3D clusters, self-assembled from adult stem cells with no planar plasticisation

Contain multiple cell-types

Mimic source organ/tissue architecture to duplicate normal or disease pathology

DRL’s leading technology can: 

Produce millions of reproducible PDOs per manufacturing batch using its patented bioprocess and bioreactors. 


Genetically diverse​

Can be used in diagnostics and personalised medicine

Model major tissue types

Wide range of cancer types, normal tissue – other therapies

Multicellular & 3D

Can be used in diagnostics and personalised medicine

Faithful & predictive

Can model by tumour or mutation subtype

Scalable & consistent

Can be used in high throughput applications

Can add immune cells

Can use in immune & cell therapy applications